Vollständiger Abstract
Worum geht es in dieser Arbeit?
Abstract Abstract 3509 Allogeneic hematopoietic cell transplantation (alloHCT) has become standard therapy for hematologic disorders and malignancies. We assessed whether overall survival (OS) at 100 days, which represents early transplant-related mortality (TRM), and at one year, which represents disease-related mortality and later TRM, had changed over time. The study population was derived from patients undergoing 38,060 first alloHCTs between 1994–2005 in US and Canadian centers and reported to the CIBMTR. Donor lymphocyte infusions were excluded. Statistical significance was measured using Ptrend over 6 time cohorts to test whether the OS estimates were stable (slope = 0), increasing (slope>0) or decreasing (slope
Bibliografischer Nachweis
Publikationsdaten
- Autor:innen
- Theresa Hahn, Philip L. McCarthy, Anna Hassebroek, John P. Klein, J. Douglas Rizzo, Susan Parsons, Steven Joffe, Navneet S. Majhail
- Quelle
- Blood
- Publikation
- 2010-01-01
- Band / Ausgabe
- Nicht angegeben
- Seiten
- Nicht angegeben
- ISSN / ISBN
- 0006-4971, 1528-0020
- Zitationen
- 0 laut Crossref
- Referenzen
- 0 hinterlegt
Zitieren
Zitierfähiger Nachweis
Theresa Hahn, Philip L. McCarthy, Anna Hassebroek, John P. Klein, J. Douglas Rizzo, Susan Parsons, Steven Joffe, Navneet S. Majhail (2010). Significant Improvement In Day 100 and 1-Year Overall Survival In Patients Who Underwent Myeloablative Allogeneic Hematopoietic Cell Transplant In the US or Canada Between 1994 and 2005. Blood. https://doi.org/10.19110/1994-5655-2026-5-62-75